209 related articles for article (PubMed ID: 22294438)
1. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.
Wu C; Wyatt AW; Lapuk AV; McPherson A; McConeghy BJ; Bell RH; Anderson S; Haegert A; Brahmbhatt S; Shukin R; Mo F; Li E; Fazli L; Hurtado-Coll A; Jones EC; Butterfield YS; Hach F; Hormozdiari F; Hajirasouliha I; Boutros PC; Bristow RG; Jones SJ; Hirst M; Marra MA; Maher CA; Chinnaiyan AM; Sahinalp SC; Gleave ME; Volik SV; Collins CC
J Pathol; 2012 May; 227(1):53-61. PubMed ID: 22294438
[TBL] [Abstract][Full Text] [Related]
2. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.
Lapuk AV; Wu C; Wyatt AW; McPherson A; McConeghy BJ; Brahmbhatt S; Mo F; Zoubeidi A; Anderson S; Bell RH; Haegert A; Shukin R; Wang Y; Fazli L; Hurtado-Coll A; Jones EC; Hach F; Hormozdiari F; Hajirasouliha I; Boutros PC; Bristow RG; Zhao Y; Marra MA; Fanjul A; Maher CA; Chinnaiyan AM; Rubin MA; Beltran H; Sahinalp SC; Gleave ME; Volik SV; Collins CC
J Pathol; 2012 Jul; 227(3):286-97. PubMed ID: 22553170
[TBL] [Abstract][Full Text] [Related]
3. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
5. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.
Dong B; Miao J; Wang Y; Luo W; Ji Z; Lai H; Zhang M; Cheng X; Wang J; Fang Y; Zhu HH; Chua CW; Fan L; Zhu Y; Pan J; Wang J; Xue W; Gao WQ
Commun Biol; 2020 Dec; 3(1):778. PubMed ID: 33328604
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.
Wyatt AW; Mo F; Wang K; McConeghy B; Brahmbhatt S; Jong L; Mitchell DM; Johnston RL; Haegert A; Li E; Liew J; Yeung J; Shrestha R; Lapuk AV; McPherson A; Shukin R; Bell RH; Anderson S; Bishop J; Hurtado-Coll A; Xiao H; Chinnaiyan AM; Mehra R; Lin D; Wang Y; Fazli L; Gleave ME; Volik SV; Collins CC
Genome Biol; 2014 Aug; 15(8):426. PubMed ID: 25155515
[TBL] [Abstract][Full Text] [Related]
7. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
8. A basal stem cell signature identifies aggressive prostate cancer phenotypes.
Smith BA; Sokolov A; Uzunangelov V; Baertsch R; Newton Y; Graim K; Mathis C; Cheng D; Stuart JM; Witte ON
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6544-52. PubMed ID: 26460041
[TBL] [Abstract][Full Text] [Related]
9. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
[TBL] [Abstract][Full Text] [Related]
10. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
11. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
12. Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.
Schlicht M; Matysiak B; Brodzeller T; Wen X; Liu H; Zhou G; Dhir R; Hessner MJ; Tonellato P; Suckow M; Pollard M; Datta MW
BMC Genomics; 2004 Aug; 5(1):58. PubMed ID: 15318950
[TBL] [Abstract][Full Text] [Related]
13. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
15. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples.
Nacu S; Yuan W; Kan Z; Bhatt D; Rivers CS; Stinson J; Peters BA; Modrusan Z; Jung K; Seshagiri S; Wu TD
BMC Med Genomics; 2011 Jan; 4():11. PubMed ID: 21261984
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.
Huang J; Wang JK; Sun Y
Curr Opin Urol; 2013 May; 23(3):189-93. PubMed ID: 23385974
[TBL] [Abstract][Full Text] [Related]
17. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
18. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
Huang YH; Zhang YQ; Huang JT
Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
